Physician profile
Alfredo E Gonzalez
NPI 1659402840
$4,497.44
in general payments reported to CMS, 2019-2025
27 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $225 · 2021: $233 · 2022: $541 · 2023: $647 · 2024: $1,107 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,502 · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,502.29 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.18 | 2019-2025 | |
| Janssen Biotech, INC. | $651.90 | 2019-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $478.67 | 2019-2025 | |
| Leo Pharma INC. | $374.28 | 2019-2025 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $308.26 | 2023-2025 | Sotyktu |
| Ucb, INC. | $245.72 | 2019-2024 | Bimzelx |
| Incyte Corporation | $235.12 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $125.14 | 2019-2020 | |
| Lilly USA, LLC | $112.13 | 2019-2024 | Taltz |
| Genzyme Corporation | $63.90 | 2022-2024 | |
| Galderma Laboratories, L.P. | $48.87 | 2019-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $42.36 | 2019 | |
| Amgen INC. | $40.35 | 2025 | Otezla |
| Dermavant Sciences, INC. | $37.31 | 2022-2023 | Vtama |
| Pfizer INC. | $35.63 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $33.84 | 2025 | Cresemba |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $30.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.94 | 2025 | Spevigo |
| Genentech USA, INC. | $25.16 | 2019 | |
| Strata Skin Sciences, INC. | $24.43 | 2019 | |
| Biofrontera INC. | $21.77 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.60 | 2025 | Ycanth |
| Botanix Sb INC | $18.44 | 2025 | Sofdra |
| Fidia Pharma USA INC. | $17.33 | 2025 | |
| Merz North America, INC. | $16.28 | 2019 | |
| Almirall LLC | $16.05 | 2023 | Klisyri |
| Mylan Pharmaceuticals INC. | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfredo Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.